E. Noseda

Influenza and Meningococcal Vaccinations Are Effective in Healthy Subjects Treated with the Interleukin-1β-Blocking Antibody Canakinumab: Results of an Open-Label, Parallel Group, Randomized, Single-Center Study

G. Del Giudice, S. Fitoussi, A. Chioato, 2010, Clinical and Vaccine Immunology.

Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center Study

A. Chioato, E. Noseda, M. Stevens, 2012, Clinical and Vaccine Immunology.

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

N. Wulffraat, P. Woo, A. Martini, 2012, Arthritis and rheumatism.

Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Study on the Pharmacodynamics of ABIO-08/01, a New CNS Drug with Potential Anxiolytic Activity

Michael Wolzt, Bernd Saletu, Peter Anderer, 2009, Neuropsychobiology.

Bioequivalence of Canakinumab Liquid Pre-Filled Syringe and Reconstituted Lyophilized Formulations Following 150 mg Subcutaneous Administration: A Randomized Study In Healthy Subjects

R. Matott, A. Dietz, A. Skerjanec, 2013, Clinical drug investigation.

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

N. Wulffraat, P. Woo, B. Bader-Meunier, 2008, Pediatric Rheumatology Online Journal.